Last reviewed · How we verify
Amicar (AMINOCAPROIC ACID)
Amicar (generic name: AMINOCAPROIC ACID) is a Antifibrinolytic Agent [EPC] Small molecule drug developed by Epic Pharma Llc. It is currently FDA-approved (first approved 1964) for Hyperfibrinolysis Induced Hemorrhage, Postsurgical Hemorrhage.
Amicar, also known as ε-Aminocaproic Acid (EACA), is a medication used to treat conditions such as thrombocytopenia and hematological malignancies, as well as to reduce blood loss in surgeries like total knee replacement. It has also been studied as a potential treatment for conditions including osteoarthritis, pulmonary arterial hypertension, and coronavirus infection (COVID-19).
At a glance
| Generic name | AMINOCAPROIC ACID |
|---|---|
| Sponsor | Epic Pharma Llc |
| Drug class | Antifibrinolytic Agent [EPC] |
| Target | Plasminogen |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1964 |
Approved indications
- Hyperfibrinolysis Induced Hemorrhage
- Postsurgical Hemorrhage
Common side effects
- Thrombosis
- Renal failure
- Rhabdomyolysis
- Myopathy
- Myositis
- Myalgia
- Muscle weakness
- Nasal congestion
- Pulmonary embolism
- Pruritis
- Rash
- Stroke
Key clinical trials
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
- Efficacy of Amicar for Children Having Craniofacial Surgery (PHASE2)
- Intrawound Administration of Vancomycin in THA (NA)
- Extended Perioperative Administration of Fibrinolysis Inhibitors After Cardiac Surgery (NA)
- A Pilot Study Comparing Anti-Inflammatory Effects Of TXA Versus EACA In Pediatric Congenital Heart Surgery (PHASE4)
- Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation (PHASE4)
- Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
- Intrawound Administration of Vancomycin in TKA (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amicar CI brief — competitive landscape report
- Amicar updates RSS · CI watch RSS
- Epic Pharma Llc portfolio CI
Frequently asked questions about Amicar
What is Amicar?
What is Amicar used for?
Who makes Amicar?
What is the generic name of Amicar?
What drug class is Amicar in?
When was Amicar approved?
What development phase is Amicar in?
What are the side effects of Amicar?
What does Amicar target?
Related
- Drug class: All Antifibrinolytic Agent [EPC] drugs
- Target: All drugs targeting Plasminogen
- Manufacturer: Epic Pharma Llc — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hyperfibrinolysis Induced Hemorrhage
- Indication: Drugs for Postsurgical Hemorrhage
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing